First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing antibody therapeutics for autoimmune and inflammatory diseases. Headquartered in San Diego, California, the company was spun off from AnaptysBio in April 2026 to independently advance its immunology pipeline. Its lead clinical programs include ANB033, a CD122 antagonist in Phase 1b development for celiac disease and eosinophilic esophagitis, and rosnilimab, a pathogenic T cell depleter that has completed Phase 2b trials for rheumatoid arthritis. The company's pipeline also features ANB101, a BDCA2 modulator in Phase 1a testing. First Tracks Biotherapeutics operates as a single business segment dedicated to the research and development of protein-based therapeutics.
The sum of declared dividends issued by a company for every ordinary share outstanding.
Dividend Yield is a financial ratio that shows how much a company pays out in dividends each year relative to its share price in the last twelve months. In the absence of any capital gains, the dividend yield is the return on investment for a stock.
It is another way that companies have to remunerate their shareholders, being an alternative to dividends. Shows the % of repurchases per share made in the last 12 months in relation to the share price.
Sum of Dividend Yield and BuyBack Yield to show the total return that the shareholder received in the last 12 months in relation to the share price.
The dividend payout ratio is the ratio of the total amount of dividends paid out to shareholders relative to the net income of the company. It is the percentage of earnings paid to shareholders via dividends.
Retained earnings (RE) are the amount of net income left over for the business after it has paid out dividends to its shareholders and are an important variable for assessing a company's financial health because it shows the net income that a company has saved over time, and therefore has the ability to reinvest in the business or distribute to shareholders.
...and much more!